Schramm W
Department of Transfusion Medicine and Haematology, University Clinic Munich, Munich, Germany.
Haemophilia. 2008 Nov;14 Suppl 5:3-10. doi: 10.1111/j.1365-2516.2008.01847.x.
Although von Willebrand disease (VWD) has a very long history, our understanding and treatment of the bleeding disorder has only evolved during the past 50 years or so. It was not until the 1920s that VWD was first recognized as a disease separate from that of classical haemophilia. It then took another 30 years before the first effective treatment was developed. Since then, the medical management of VWD has evolved considerably, but not without its ups and downs. One of the key milestones in the evolution of the treatment of VWD was the development of Haemate P/Humate-P (CSL Behring) - the first virus-inactivated factor VIII plasma product. For 25 years, this concentrate has demonstrated excellent clinical efficacy and safety for patients with VWD and for those with haemophilia. This article provides an historical overview of the early landmark efforts to ensure a safe plasma-derived replacement product and outlines the clinical evolution in the use of Haemate P.
尽管血管性血友病（VWD）有着很长的历史，但我们对这种出血性疾病的认识和治疗仅在过去50年左右才有所发展。直到20世纪20年代，VWD才首次被确认为一种与经典血友病不同的疾病。又过了30年，才开发出第一种有效的治疗方法。从那时起，VWD的药物治疗有了很大的发展，但并非一帆风顺。VWD治疗发展的关键里程碑之一是Haemate P/Humate-P（CSL Behring）的开发——第一种病毒灭活的VIII因子血浆产品。25年来，这种浓缩物已证明对VWD患者和血友病患者具有出色的临床疗效和安全性。本文提供了早期确保安全的血浆源性替代产品的标志性努力的历史概述，并概述了Haemate P使用中的临床演变。
